048530 — iNtRON Biotechnology Income Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapMomentum Trap

Annual income statement for iNtRON Biotechnology, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st	2025 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Revenue
Total Revenue	29,308	14,007	9,585	6,418	5,740
Cost of Revenue
Gross Profit	21,772	9,658	5,843	3,737	3,105
Selling / General / Administrative Expenses
Research And Development
Depreciation and Amortization
Unusual Expense / Income
Total Operating Expenses	19,230	15,480	18,621	11,655	13,638
Operating Profit	10,078	-1,473	-9,035	-5,238	-7,898
Gain / Loss on Sale of Assets
Total Net Non Operating Interest Income / Expense
Other Net Non Operating Costs
Net Income Before Taxes	10,575	8,319	-10,837	-3,006	-9,033
Provision for Income Taxes
Net Income After Taxes	9,728	5,712	-9,695	-2,591	-8,958
Minority Interest
Net Income Before Extraordinary Items
Net Income	9,728	5,712	-9,695	-2,591	-8,958
Income Available to Common Shareholders Excluding Extraordinary Items
Income Available to Common Shareholders Including Extraordinary Items
Dilution Adjustment
Diluted Net Income	9,728	-12.3	-9,695	-2,591	-8,958
Diluted Weighted Average Shares
Basic EPS Including Extraordinary Items
Diluted EPS Including Extraordinary Items
Diluted EPS Excluding Extraordinary Items
Normalised Income Before Taxes
Normalised Income After Taxes
Normalised Income Available to Common Shareholders
Diluted Normalised EPS	290	0.892	-179	-91.3	-280
Dividends per Share